Here’s whether Crinetics Pharmaceuticals, Inc. (CRNX) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+17.14% over 10 days); strong 1-year return of +188.1%; 3-month momentum positive (+130.1%). Concerns: RSI 87 — overbought, elevated pullback risk. Currently 0.1% off its 52-week high. Score: +5/7.
CRNX is in a confirmed uptrend, trading above both its 50-day ($68.85) and 200-day ($49.16) moving averages. With an RSI of 87.2, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +188.1% compares to +20.5% for SPY (beat the market by 167.6%).
$10,000 invested 1 year ago→ $28,806 today
vs. S&P 500 (SPY) — same period beat market by 167.6%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($49.16)
✓Above 50-day MA ($68.85)
!RSI(14) neutral zone (30–70) — currently 87.2
✓Positive return (+188.1%)
✓Within 10% of period high (−0.1%)
Period Range $84.69
$28.73$84.80
RSI (14) 87.2
0 · OversoldOverbought · 100
Key Metrics
Price$84.69
Period Return+188.1%
Period High$84.80
Period Low$28.73
Drawdown−0.1%
MA-50$68.85
MA-200$49.16
RSI (14)87.2
Avg Volume (30d)3.2M
vs. SPYbeat by 167.6%
Return Rank#61 of 999
Trend Signals
Price is above the 200-day moving average ($49.16)